STOCK TITAN

[Form 4] Traws Pharma, Inc. Insider Trading Activity

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4
Rhea-AI Filing Summary

Traws Pharma (NASDAQ:TRAW) filed a routine Form 4 reporting an insider equity grant. Director Jack E. Stover received 23,000 non-qualified stock options on 06/19/2025 at an exercise price of $1.65 per share. The options vest 100 % on the first anniversary of the grant date and expire on 06/19/2035. No open-market purchases or sales of common stock were disclosed, and the grant carries no immediate cash value to the director. Following the transaction, Stover beneficially owns 23,000 derivative securities, all held directly.

Traws Pharma (NASDAQ:TRAW) ha presentato un modulo Form 4 di routine per segnalare una concessione di azioni interne. Il direttore Jack E. Stover ha ricevuto 23.000 opzioni su azioni non qualificate il 19/06/2025, con un prezzo di esercizio di $1,65 per azione. Le opzioni maturano per il 100% al primo anniversario della data di concessione e scadono il 19/06/2035. Non sono stati rivelati acquisti o vendite di azioni ordinarie sul mercato aperto e la concessione non comporta alcun valore in contanti immediato per il direttore. Dopo l'operazione, Stover detiene beneficiariamente 23.000 strumenti derivati, tutti posseduti direttamente.

Traws Pharma (NASDAQ:TRAW) presentó un formulario Form 4 rutinario para informar sobre una concesión de acciones internas. El director Jack E. Stover recibió 23,000 opciones sobre acciones no calificadas el 19/06/2025 con un precio de ejercicio de $1.65 por acción. Las opciones se consolidan al 100% en el primer aniversario de la fecha de concesión y vencen el 19/06/2035. No se divulgaron compras o ventas en el mercado abierto de acciones ordinarias, y la concesión no tiene valor en efectivo inmediato para el director. Tras la transacción, Stover posee beneficiosamente 23,000 valores derivados, todos mantenidos directamente.

Traws Pharma (NASDAQ:TRAW)는 내부자 주식 부여를 보고하는 정기 Form 4를 제출했습니다. 이사 Jack E. Stover는 2025년 6월 19일에 주당 $1.65의 행사가격으로 23,000개의 비자격 주식 옵션을 받았습니다. 이 옵션은 부여일로부터 1주년 기념일에 100% 취득되며, 2035년 6월 19일에 만료됩니다. 일반 주식의 공개 시장 매매는 공개되지 않았으며, 이 부여는 이사에게 즉각적인 현금 가치를 제공하지 않습니다. 거래 후 Stover는 모두 직접 보유한 23,000개의 파생 증권을 실질적으로 소유하게 됩니다.

Traws Pharma (NASDAQ:TRAW) a déposé un formulaire Form 4 de routine signalant une attribution d’actions interne. Le directeur Jack E. Stover a reçu 23 000 options d’achat d’actions non qualifiées le 19/06/2025, à un prix d’exercice de 1,65 $ par action. Les options deviennent entièrement acquises à la date du premier anniversaire de l’attribution et expirent le 19/06/2035. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été divulgué, et cette attribution ne confère aucune valeur monétaire immédiate au directeur. Suite à cette opération, Stover détient bénéficiairement 23 000 titres dérivés, tous détenus directement.

Traws Pharma (NASDAQ:TRAW) hat routinemäßig ein Formular 4 eingereicht, um eine Insider-Aktienzuteilung zu melden. Direktor Jack E. Stover erhielt am 19.06.2025 23.000 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von 1,65 $ pro Aktie. Die Optionen werden zu 100 % am ersten Jahrestag des Zuteilungsdatums fällig und verfallen am 19.06.2035. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt bekannt gegeben, und die Zuteilung hat keinen unmittelbaren Barwert für den Direktor. Nach der Transaktion besitzt Stover wirtschaftlich 23.000 derivative Wertpapiere, die alle direkt gehalten werden.

Positive
  • None.
Negative
  • None.

Traws Pharma (NASDAQ:TRAW) ha presentato un modulo Form 4 di routine per segnalare una concessione di azioni interne. Il direttore Jack E. Stover ha ricevuto 23.000 opzioni su azioni non qualificate il 19/06/2025, con un prezzo di esercizio di $1,65 per azione. Le opzioni maturano per il 100% al primo anniversario della data di concessione e scadono il 19/06/2035. Non sono stati rivelati acquisti o vendite di azioni ordinarie sul mercato aperto e la concessione non comporta alcun valore in contanti immediato per il direttore. Dopo l'operazione, Stover detiene beneficiariamente 23.000 strumenti derivati, tutti posseduti direttamente.

Traws Pharma (NASDAQ:TRAW) presentó un formulario Form 4 rutinario para informar sobre una concesión de acciones internas. El director Jack E. Stover recibió 23,000 opciones sobre acciones no calificadas el 19/06/2025 con un precio de ejercicio de $1.65 por acción. Las opciones se consolidan al 100% en el primer aniversario de la fecha de concesión y vencen el 19/06/2035. No se divulgaron compras o ventas en el mercado abierto de acciones ordinarias, y la concesión no tiene valor en efectivo inmediato para el director. Tras la transacción, Stover posee beneficiosamente 23,000 valores derivados, todos mantenidos directamente.

Traws Pharma (NASDAQ:TRAW)는 내부자 주식 부여를 보고하는 정기 Form 4를 제출했습니다. 이사 Jack E. Stover는 2025년 6월 19일에 주당 $1.65의 행사가격으로 23,000개의 비자격 주식 옵션을 받았습니다. 이 옵션은 부여일로부터 1주년 기념일에 100% 취득되며, 2035년 6월 19일에 만료됩니다. 일반 주식의 공개 시장 매매는 공개되지 않았으며, 이 부여는 이사에게 즉각적인 현금 가치를 제공하지 않습니다. 거래 후 Stover는 모두 직접 보유한 23,000개의 파생 증권을 실질적으로 소유하게 됩니다.

Traws Pharma (NASDAQ:TRAW) a déposé un formulaire Form 4 de routine signalant une attribution d’actions interne. Le directeur Jack E. Stover a reçu 23 000 options d’achat d’actions non qualifiées le 19/06/2025, à un prix d’exercice de 1,65 $ par action. Les options deviennent entièrement acquises à la date du premier anniversaire de l’attribution et expirent le 19/06/2035. Aucun achat ou vente d’actions ordinaires sur le marché ouvert n’a été divulgué, et cette attribution ne confère aucune valeur monétaire immédiate au directeur. Suite à cette opération, Stover détient bénéficiairement 23 000 titres dérivés, tous détenus directement.

Traws Pharma (NASDAQ:TRAW) hat routinemäßig ein Formular 4 eingereicht, um eine Insider-Aktienzuteilung zu melden. Direktor Jack E. Stover erhielt am 19.06.2025 23.000 nicht qualifizierte Aktienoptionen zu einem Ausübungspreis von 1,65 $ pro Aktie. Die Optionen werden zu 100 % am ersten Jahrestag des Zuteilungsdatums fällig und verfallen am 19.06.2035. Es wurden keine Käufe oder Verkäufe von Stammaktien am offenen Markt bekannt gegeben, und die Zuteilung hat keinen unmittelbaren Barwert für den Direktor. Nach der Transaktion besitzt Stover wirtschaftlich 23.000 derivative Wertpapiere, die alle direkt gehalten werden.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
STOVER JACK E

(Last) (First) (Middle)
C/O TRAWS PHARMA, INC
12 PENNS TRAIL

(Street)
NEWTOWN PA 18940

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Traws Pharma, Inc. [ TRAW ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
06/19/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to purchase) $1.65 06/19/2025 A 23,000 06/19/2026(1) 06/19/2035 Common Stock 23,000 $0 23,000 D
Explanation of Responses:
1. These options vest 100% on the first anniversary of the grant date.
/s/ Jack E. Stover 06/23/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many stock options did TRAW director Jack E. Stover receive?

The filing states that Mr. Stover was granted 23,000 stock options on 06/19/2025.

What is the exercise price and vesting schedule of the new options for [[**TRAW**]]?

Each option can be exercised at $1.65 per share and vests 100 % on 06/19/2026, one year after the grant date.
Traws Pharma

NASDAQ:TRAW

TRAW Rankings

TRAW Latest News

TRAW Latest SEC Filings

TRAW Stock Data

9.13M
3.50M
18.86%
31.23%
2.73%
Biotechnology
Pharmaceutical Preparations
Link
United States
NEWTOWN